A citation-based method for searching scientific literature


List of co-cited articles
372 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
30

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Laurie H Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J Savage, Tamara Shenkier, Judy Sutherland,[...]. Blood 2007
900
26

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Bertrand Coiffier, Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard,[...]. N Engl J Med 2002
24

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Bruce D Cheson, Richard I Fisher, Sally F Barrington, Franco Cavalli, Lawrence H Schwartz, Emanuele Zucca, T Andrew Lister. J Clin Oncol 2014
22

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Zheng Zhou, Laurie H Sehn, Alfred W Rademaker, Leo I Gordon, Ann S Lacasce, Allison Crosby-Thompson, Ann Vanderplas, Andrew D Zelenetz, Gregory A Abel, Maria A Rodriguez,[...]. Blood 2014
489
17

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
A A Alizadeh, M B Eisen, R E Davis, C Ma, I S Lossos, A Rosenwald, J C Boldrick, H Sabet, T Tran, X Yu,[...]. Nature 2000
17

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu,[...]. Blood 2017
646
17

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Christine P Hans, Dennis D Weisenburger, Timothy C Greiner, Randy D Gascoyne, Jan Delabie, German Ott, H Konrad Müller-Hermelink, Elias Campo, Rita M Braziel, Elaine S Jaffe,[...]. Blood 2004
17

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Bjoern Chapuy, Chip Stewart, Andrew J Dunford, Jaegil Kim, Atanas Kamburov, Robert A Redd, Mike S Lawrence, Margaretha G M Roemer, Amy J Li, Marita Ziepert,[...]. Nat Med 2018
649
16

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Bertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, Gérard Lepeu, Isabelle Plantier, Sylvie Castaigne, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban,[...]. Blood 2010
895
15

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Roland Schmitz, George W Wright, Da Wei Huang, Calvin A Johnson, James D Phelan, James Q Wang, Sandrine Roulland, Monica Kasbekar, Ryan M Young, Arthur L Shaffer,[...]. N Engl J Med 2018
749
15

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Thomas M Habermann, Edie A Weller, Vicki A Morrison, Randy D Gascoyne, Peter A Cassileth, Jeffrey B Cohn, Shaker R Dakhil, Bruce Woda, Richard I Fisher, Bruce A Peterson,[...]. J Clin Oncol 2006
11

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.
Marita Ziepert, Dirk Hasenclever, Evelyn Kuhnt, Bertram Glass, Norbert Schmitz, Michael Pfreundschuh, Markus Loeffler. J Clin Oncol 2010
380
10

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Michael Pfreundschuh, Lorenz Trümper, Anders Osterborg, Ruth Pettengell, Marek Trneny, Kevin Imrie, David Ma, Devinder Gill, Jan Walewski, Pier-Luigi Zinzani,[...]. Lancet Oncol 2006
10

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
George W Wright, Da Wei Huang, James D Phelan, Zana A Coulibaly, Sandrine Roulland, Ryan M Young, James Q Wang, Roland Schmitz, Ryan D Morin, Jeffrey Tang,[...]. Cancer Cell 2020
199
10

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg,[...]. J Clin Oncol 2010
969
9

Revised response criteria for malignant lymphoma.
Bruce D Cheson, Beate Pfistner, Malik E Juweid, Randy D Gascoyne, Lena Specht, Sandra J Horning, Bertrand Coiffier, Richard I Fisher, Anton Hagenbeek, Emanuele Zucca,[...]. J Clin Oncol 2007
9

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Umberto Vitolo, Marek Trněný, David Belada, John M Burke, Angelo Michele Carella, Neil Chua, Pau Abrisqueta, Judit Demeter, Ian Flinn, Xiaonan Hong,[...]. J Clin Oncol 2017
226
8

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
8

Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma.
Myriam Sasanelli, Michel Meignan, Corinne Haioun, Alina Berriolo-Riedinger, René-Olivier Casasnovas, Alberto Biggi, Andrea Gallamini, Barry A Siegel, Amanda F Cashen, Pierre Véra,[...]. Eur J Nucl Med Mol Imaging 2014
124
8

Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.
N George Mikhaeel, Daniel Smith, Joel T Dunn, Michael Phillips, Henrik Møller, Paul A Fields, David Wrench, Sally F Barrington. Eur J Nucl Med Mol Imaging 2016
143
8

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.
Lindsay M Morton, Sophia S Wang, Susan S Devesa, Patricia Hartge, Dennis D Weisenburger, Martha S Linet. Blood 2006
7

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
David W Scott, Anja Mottok, Daisuke Ennishi, George W Wright, Pedro Farinha, Susana Ben-Neriah, Robert Kridel, Garrett S Barry, Christoffer Hother, Pau Abrisqueta,[...]. J Clin Oncol 2015
222
7

Stromal gene signatures in large-B-cell lymphomas.
G Lenz, G Wright, S S Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, N Goldschmidt, J Iqbal,[...]. N Engl J Med 2008
7

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, Rudolf Schmits, Martin Mohren, Eva Lengfelder, Marcel Reiser, Christina Nickenig, Michael Clemens, Norma Peter,[...]. Lancet Oncol 2008
772
7

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
807
7

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Laurie H Sehn, Alex F Herrera, Christopher R Flowers, Manali K Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhit Ozcan,[...]. J Clin Oncol 2020
235
7

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, Eric D Hsi, Matthew J Maurer, Levi D Pederson, Mei-Yin C Polley, Brandelyn N Pitcher, Bruce D Cheson, Brad S Kahl,[...]. J Clin Oncol 2019
150
7

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
Amy S Ruppert, Jesse G Dixon, Gilles Salles, Anna Wall, David Cunningham, Viola Poeschel, Corinne Haioun, Herve Tilly, Herve Ghesquieres, Marita Ziepert,[...]. Blood 2020
42
16

High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Laetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, Hervé Tilly, Pierre Feugier, Loic Chartier, Christophe Fruchart, Louise Roulin, Lucie Oberic, Gian Matteo Pica,[...]. Blood 2020
39
17

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Frédéric Peyrade, Fabrice Jardin, Catherine Thieblemont, Antoine Thyss, Jean-François Emile, Sylvie Castaigne, Bertrand Coiffier, Corinne Haioun, Serge Bologna, Olivier Fitoussi,[...]. Lancet Oncol 2011
287
7

Follicular lymphoma international prognostic index.
Philippe Solal-Céligny, Pascal Roy, Philippe Colombat, Josephine White, Jim O Armitage, Reyes Arranz-Saez, Wing Y Au, Monica Bellei, Pauline Brice, Dolores Caballero,[...]. Blood 2004
6

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
H Tilly, M Gomes da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, J Walewski, M André, P W Johnson, M Pfreundschuh,[...]. Ann Oncol 2015
402
6

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
Andreas Rosenwald, George Wright, Wing C Chan, Joseph M Connors, Elias Campo, Richard I Fisher, Randy D Gascoyne, H Konrad Muller-Hermelink, Erlend B Smeland, Jena M Giltnane,[...]. N Engl J Med 2002
6


Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Anas Younes, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Jun Zhu, Caterina Patti, David Belada, Olga Samoilova, Cheolwon Suh,[...]. J Clin Oncol 2019
193
6

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Nathalie A Johnson, Graham W Slack, Kerry J Savage, Joseph M Connors, Susana Ben-Neriah, Sanja Rogic, David W Scott, King L Tan, Christian Steidl, Laurie H Sehn,[...]. J Clin Oncol 2012
636
6

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Andrew Davies, Thomas E Cummin, Sharon Barrans, Tom Maishman, Christoph Mamot, Urban Novak, Josh Caddy, Louise Stanton, Shamim Kazmi-Stokes, Andrew McMillan,[...]. Lancet Oncol 2019
94
6


Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano,[...]. Nat Med 2015
671
6

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis,[...]. Lancet 2020
391
6

18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome.
Anne-Ségolène Cottereau, Christophe Nioche, Anne-Sophie Dirand, Jérôme Clerc, Franck Morschhauser, Olivier Casasnovas, Michel Meignan, Irène Buvat. J Nucl Med 2020
39
15

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.
Andrea Gallamini, Caterina Stelitano, Roberta Calvi, Monica Bellei, Daniele Mattei, Umberto Vitolo, Fortunato Morabito, Maurizio Martelli, Ercole Brusamolino, Emilio Iannitto,[...]. Blood 2004
417
6

Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.
Qaid Ahmed Shagera, Gi Jeong Cheon, Youngil Koh, Min Young Yoo, Keon Wook Kang, Dong Soo Lee, E Edmund Kim, Sung-Soo Yoon, June-Key Chung. Eur J Nucl Med Mol Imaging 2019
29
20


Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Anupama Reddy, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt, Cassandra L Love, Alexander Waldrop, Sirpa Leppa, Annika Pasanen, Leo Meriranta, Marja-Liisa Karjalainen-Lindsberg,[...]. Cell 2017
498
6

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
T Philip, C Guglielmi, A Hagenbeek, R Somers, H Van der Lelie, D Bron, P Sonneveld, C Gisselbrecht, J Y Cahn, J L Harousseau. N Engl J Med 1995
5

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Tina Marie Green, Ken H Young, Carlo Visco, Zijun Y Xu-Monette, Attilio Orazi, Ronald S Go, Ole Nielsen, Ole V Gadeberg, Torben Mourits-Andersen, Mikael Frederiksen,[...]. J Clin Oncol 2012
471
5

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Grzegorz S Nowakowski, Betsy LaPlant, William R Macon, Craig B Reeder, James M Foran, Garth D Nelson, Carrie A Thompson, Candido E Rivera, David J Inwards, Ivana N Micallef,[...]. J Clin Oncol 2015
266
5

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Annette M Staiger, Marita Ziepert, Heike Horn, David W Scott, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Monika Szczepanowski, Michael Hummel,[...]. J Clin Oncol 2017
127
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.